Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Amgen Inc. lost requests for several judgments in Lindis Biotech GmbH’s patent-infringement lawsuit seeking damages for sales of the leukemia treatment Blincyto, according to a federal judge’s mixed ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.

Analysts chewed over early data showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

In a few weeks, Howard Chang, M.D., Ph.D., will join Amgen, filling both the roles of senior vice president of research and ...

Analysts' ratings for Amgen AMGN over the last quarter vary from bullish to bearish, as provided by 11 analysts. The ...